Perceptive Advisors’s Ocular Therapeutix OCUL Stock Holding History

Perceptive Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.24M	Buy	+500,000	New	+$4.77M	0.08%	77

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Perceptive Advisors's OCUL Position: Q2 2025 in Review

Perceptive Advisors sold out of Ocular Therapeutix (OCUL) in Q2 2025, closing a stake of 915,775 shares — an estimated $6.71M sold.

Perceptive Advisors first reported a position in OCUL in Q1 2024 and held it in 5 quarters. The position peaked at $30.3M in Q1 2024. 186 funds tracked by Wall St. Rank hold OCUL as of Q2 2025.

Perceptive Advisors reported no remaining Ocular Therapeutix position as of Q2 2025 after selling out during the quarter.
Perceptive Advisors sold 915,775 Ocular Therapeutix shares in Q2 2025, an estimated $6.71M.
Perceptive Advisors first reported a position in Ocular Therapeutix in Q1 2024 and held it in 5 quarters.
Perceptive Advisors's Ocular Therapeutix position peaked at $30.3M in Q1 2024.
186 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2025.

Based on Perceptive Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.